16 September 2026 note archive · Trial
TIRTLE2: acute metabolic effects of tirzepatide in T1D: review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT06820281; RECRUITING; updated 2026-08-10; enrollment 44 (ESTIMATED); results not posted.
Endpoint comparison: Whole-body insulin sensitivity (6 weeks).
Sources for this record: TIRTLE2: Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.